Lilly’s Hotly Anticipated Oral Weight Loss Drug Delivers Lukewarm Results in Phase III
Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med.Read more:
biospace.comBiotechnology